Mild Alzheimer's Disease

Neurology
2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Longeveron
LongeveronMIAMI, FL
1 program
1
Allogeneic MSCPhase 21 trial
Active Trials
NCT05233774Completed50Est. Sep 2023
Ionis Pharmaceuticals
1 program
1
IONIS MAPTRxPhase 11 trial
Active Trials
NCT03186989Completed46Est. May 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
LongeveronAllogeneic MSC
Ionis PharmaceuticalsIONIS MAPTRx

Clinical Trials (2)

Total enrollment: 96 patients across 2 trials

NCT05233774LongeveronAllogeneic MSC

Lomecel-B Effects on Alzheimer's Disease

Start: Dec 2021Est. completion: Sep 202350 patients
Phase 2Completed
NCT03186989Ionis PharmaceuticalsIONIS MAPTRx

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's Disease

Start: Oct 2017Est. completion: May 202246 patients
Phase 1Completed

Related Jobs in Neurology

Director, Distribution & Services

Xenon Pharmaceuticals
Remote
7h ago

Senior Medical Science Liaison (NYC Tri-State)

Xenon Pharmaceuticals
Remote
7h ago
$208K - $234K/yr

Director of Medical Affairs

CoMind
Miami, FL
7h ago

Director of Finance

CoMind
London, UK
7h ago

Electronics Engineering Manager

CoMind
London, UK
7h ago

Director of Information Technology

Zavation Medical Products
7h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 companies competing in this space

Related Indications

Multiple Sclerosis(274)Schizophrenia(255)Epilepsy(242)Parkinson Disease(171)Alzheimer's Disease(165)Parkinson's Disease(160)Alzheimer Disease(117)Stroke(102)Relapsing-Remitting Multiple Sclerosis(83)Depression(82)